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ABSTRACT
Background. Chronic kidney disease (CKD) patients under hemodialysis show a higher risk of cardiovascular (CV) mortality
and morbidity than the general population. This study aims to identify genetic markers that could explain the increased CV
risk in hemodialysis.
Methods. A total of 245 CKD patients under hemodialysis were recruited and followed up for 5 years to record CV events.
Genetic analysis was performed using single-nucleotide polymorphisms (SNPs) genotyping by Infinium Expanded Multi-
Ethnic Genotyping Array (Illumina, San Diego, CA, USA) comparing patients with and without a history of CV events [161
cardiovascular diseases (CVDs) and 84 no CVDs]. The fixation index (Fst) measure was used to identify the most
differentiated SNPs, and gene ontology analysis [Protein Analysis THrough Evolutionary Relationships (PANTHER) and
Ingenuity Pathway Analysis (IPA)] was applied to define the biological/pathological roles of the associated SNPs. Partitioning
tree analysis interrogated the genotype–phenotype relationship between discovered genetic variants and CV phenotypes.
Cox regression analysis measured the effect of these SNPs on new CV events during the follow-up (FU).
Results. Fst analysis identified 3218 SNPs that were significantly different between CVD and no CVD. Gene ontology analysis
identified two of these SNPs as involved in cardiovascular disease pathways (Ingenuity Pathway) and heart development
(Panther) and belonging to 2 different genes: Glucagon-like peptide-1 receptor (GLP1R) and Sarcoglycan delta (SGCD). The
phenotype–genotype analysis found a higher percentage of CVD patients carrying the GLP1R rs10305445 allele A (P¼0.03)
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and lower percentages of CVD patients carrying the SGCD rs145292439 allele A (P¼0.038). Moreover, SGCD rs145292439 was
associated with higher levels of high-density lipoprotein (P¼0.015). Cox analysis confirmed the increased frequency of CV
events during the 5-year FU in patients carrying GLP1R rs1035445 allele A but it did not show any significant association
with SGCD rs145292439.
Conclusions. This study identified GLP1R rs10305445 and SCGD rs145292439 as potential genetic markers that may explain
the higher risk of CVD in hemodialysis patients.
Keywords: cardiovascular disease, chronic kidney disease, genetics, gene polymorphism, hemodialysis
INTRODUCTION
Cardiovascular disease (CVD) is the main cause of death and
morbidity in patients with chronic kidney disease (CKD). The in-
cidence of cardiovascular (CV) mortality is 10–20 times higher in
CKD patients compared with the general population and it
increases with the severity of CKD. Consequently, 20% of he-
modialysis patients die for CV events each year [1–5].
Traditional predisposing factors have been demonstrated to not
to play a role in predicting CV risk in CKD patients; nevertheless,
CV risk in CKD has been associated to mineral metabolism
alterations, anemia and uremic toxin levels that may lead to
vascular and coronary stiffness and left ventricular hypertrophy
[6–9].
Twin and family studies have documented the heritability of
susceptibility to CV events in patients with normal renal func-
tion. Genetic studies and genome-wide association studies
(GWASs) have identified multiple loci associated with potential
causal factors as well as pathophysiological pathways and
therapeutic targets implicated in CVD [10, 11].
Studies in CKD patients investigated single candidate genes
potentially involved in CV risk, and found potentially genetic
risk factors, such as Kelch Like ECH Associated Protein 1
(Keap1), Vascular Endothelial Growth Factor (VEGF), Monocyte
Chemotactic Protein-1 (MCP-1), Interleukin 6 (IL-6), Nuclear
Erythroid Factor 2 (Nrf2), Vitamin D Receptor (VDR), Heme
Oxigenase 1 (HMOX1) and Receptor of Advanced Glycosylation
End-Product (RAGE). [12–19]. No GWASs were conducted in CKD
patients to explore genes and their variants associated with
CVD. A recent study investigated the genetic risk of CVD in CKD
[20] using a multilocus risk factor score, as the sum of the num-
ber of risk alleles across 9 variants identified from a GWAS in
patients with normal kidney function. This score was able to
predict an increase in coronary heart disease in CKD Stages 4
and 5 patients more accurately than traditional risk factors [21].
The aim of this study was to interrogate the whole-genome
variants to identify genetic markers for CVD in CKD patients
undergoing hemodialysis. We genotyped 245 hemodialysis
patients using Infinium Expanded Multi-Ethnic Genotyping
Array (MEGAEX; Illumina, San Diego, CA, USA) and correlated
those variants to the patients’ history of CV events and to new
events occurring during a 5-year follow-up (FU).
MATERIALS ANDMETHODS
Patients, clinical data and samples
A total of 245 hemodialysis patients were enrolled in a prospec-
tive study from three dialysis centers in Milan (Italy): San
Raffaele Hospital, San Paolo Hospital and Cernusco sul Naviglio
Uboldo Hospital. CKD causes are summarized in Supplementary
data, Table S1 and the patients were treated according to the
clinical guidelines and patient needs. Exclusion criteria were a
5-year history of neoplasia, acute kidney disorders, liver insuffi-
ciency or cirrhosis, malabsorption, dementia and motorial in-
ability and autoimmune disorders.
Incident CV events were recorded during a 5-year FU; previ-
ous CV events were documented from clinical records (the in-
cluded CVD are listed in the Supplementary data file). All-cause
mortality was also considered. Patients were grouped into two
subpopulations: individuals with or without a history of CV
events (CVD and no CVD, respectively). Secondarily, patients
after the 5-year FU were reclassified for the absence or presence
of new CV events (CVD at FU and no CVD at FU, respectively).
Serum concentrations of phosphate, total calcium, creati-
nine, C-reactive protein (CRP), 25-hydroxyvitamin D [25(OH)D],
1,25-dihydroxy-vitamin D [1,25(OH)2D], intact parathyroid hor-
mone (PTH) and fibroblast growth factor 23 (FGF23) were mea-
sured at the study baseline. In particular, PTH and 1,25(OH)2D
were measured by chemiluminescence immunoassay (CLIA);
25(OH)D by radioimmunoassay CLIA (DiaSorin, Stillwater, MN,
USA); and full-length FGF23 by a two-step enzyme-linked im-
munoassay method (Kainos Laboratories, Tokyo, Japan) [22].
Peripheral blood samples were collected at the baseline in ethyl-
enediaminetetraacetic acid (EDTA) tubes and stored for geno-
typing analysis.
The study was approved by the San Raffaele Scientific
Institute Ethical Committee. All participants signed informed
consent to participate in this study.
Genotyping
Genomic DNA was extracted from EDTA blood samples using
the NucleoSpin Blood DNA Isolation kit (Macherey-Nagel,
Du¨ren, Germany). DNA was checked for quantity and quality us-
ing Nanodrop (Thermo Fisher Scientific, Waltham, MA, USA)
and FlexStation3 (Molecular Devices, San Jose, CA, USA) and
then processed for genotyping using the MEGAEX. See the de-
tailed method in the Supplementary data.
Statistics
Phenotypic data were expressed as mean6 standard deviation.
Differences between mean values were assessed using
Student’s t-test. A two-sided P-value< 0.05 (after Bonferroni cor-
rection) was considered indicative of statistical significance.
Pairwise identity was calculated by state between individu-
als using PLINK version 1.07 [23], and all close relatives were re-
moved up to the second cousin using a qˆ cut-off of 0.125. The
initial dataset composed of 245 genotyped individuals was re-
duced to 208 unrelated individuals.
For analyses of markers with a steep difference in allele
frequency between no CVD and CVD, the following filters were
applied: minor allele frequency > 0.05, Hardy–Weinberg equilib-
rium exact test P> 17, marker in linkage disequilibrium
(r2> 0.4) and genotyping rate> 0.99.
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Subsequently the fixation index (Fst) was estimated [24] as a
measure of genetic differentiation for the same marker between
two subpopulations in order to find the most differentiated sin-
gle-nucleotide polymorphisms (SNPs) among no CVD and CVD
patients taking only the variants that fall over the 99th percen-
tile of the genome-wide Fst distribution. Variants were anno-
tated using the variant effect predictor (VEP) [25]. Gene ontology
analyses were performed using Protein Analysis THrough
Evolutionary Relationships (PANTHER) [26]. Pathways analyses
were performed using Ingenuity Pathway Analysis (IPA) [27].
Conditional inference-based recursive partitioning (hereafter
‘tree regression analysis’) implemented in the R ‘party’ package
[28] was used to describe the genotype–phenotype relationship be-
tween genetic variants discovered, covariates and CV phenotype.
The procedure utilizes the variable with the lowest P-value (after
Bonferroni correction) as the first node of the decision tree; subse-
quently, subgroups are created and the variable with the lowest
P-value (if there is one) is taken as the second or third node.
SNPs associated with the previous history of CV events were
then tested for the association with new CV events during the
5-year FU using two Cox regression models. The first model in-
cluded variables associated with CV events in the univariate
analysis and the second considered variables potentially impli-
cated in CV events. The odds ratio (OR) and 95% confidence in-
terval (CI) were calculated to express the risk of CV events
related to the patient genotype.
Statistical analyses were conducted using SPSS Statistics (IBM,
Armonk, NY, USA) and R (R Foundation, Vienna, Austria) [28].
Predictive functional analysis
Prediction tools were used to test any function effect of SNPs as-
sociated with CV events on the respective genes. The
RegulomeDB database annotates SNPs with known and predicted
regulatory DNA elements in the human genome, including
regions of DNAase hypersensitivity, binding sites of transcription
factors and promoter regions [29]. HaploReg version 4.1 explores
annotations of SNPs for chromatin state, protein-binding annota-
tion, sequence conservation across mammals and the effect on
regulatory motifs and on expression from expression
quantitative trait loci studies [30]. The SNP identification (rs#
from the dbSNP database) was used as data for entry into both
RegulomeDB and HaploReg. Match 1.0 Public is a weight matrix–
based program for predicting transcription factor binding sites in
DNA sequences that uses a library of positional weight matrices
from TRANSFAC 6.0 [31]. Sequences (100 nt) for each variant
were imputed as FASTA format.
RESULTS
Patients’ characteristics
Among 245 participants, 161 patients (65.7%) had suffered from
previous CV events (CVD). Compared with 84 patients without a
CV history (no CVD), these patients were older, spent more time
on dialysis, had a higher incidence of hypertension and had
higher CRP values. They also developed more CV events during
the 5-year FU (Table 1).
Seventy-nine patients suffered from CV events during the
5-year FU and they were characterized by a higher percentage of
past CV events, increased body weight and lower serum PTH.
The effect of age, dialysis vintage and hypertension was con-
firmed with the CV events recorded during the FU (Table 2).
Genetic analysis
A SNP genotyping array was used to investigate potential ge-
netic markers predisposing to CVD in hemodialysis patients.
From an initial dataset of 245 genotyped patients, the geneti-
cally close relatives were removed and 208 unrelated individu-
als were used for the analysis (Supplementary data, Figure S1).
At the baseline, from 208 subjects, we defined a group of 135
CVD subjects and a group of 73 no CVD subjects that shared
similar clinical characteristics of the entire population at base-
line and at FU (Supplementary data, Tables S2 and S3).
After applying genetic analysis filters, 321 788 polymorphic
variants were obtained from the 2million interrogated SNPs.
The Fst was estimated as a measure of the genetic differentia-
tion between CVD and no CVD and resulted in 3218 markers
with Fst >99th percentile of the genome-wide distribution
Table 1. Characteristics of patients divided according to CV history
Variables Total patients Patients CVD Patients no CVD P-value
Patients, n (M/F) 245 (168/77) 161(112/49) 84(56/28) 0.64
Age (years) 676 14 706 12 62615 0.0001
Body weight (kg) 666 14 666 14 66613 0.87
Dialysis vintage (months) 626 64 716 67 45655 0.002
Serum creatinine (mg/dL) 8.346 2.36 8.256 2.25 8.5162.54 0.41
Serum calcium (mmol/L) 2.226 0.18 2.216 0.18 2.2460.18 0.15
Serum phosphate (mmol/L) 1.486 0.54 1.446 0.55 1.5560.53 0.15
Serum protein (g/dL) 6.546 0.67 6.556 0.68 6.5360.69 0.81
Serum PTH (pg/mL) 2356 197 2286 197 2486197 0.44
Serum 1,25(OH)2D (pg/mL) 10.36 10.1 9.56 6.2 11.7614.5 0.23
Serum 25(OH)D (ng/mL) 13.16 9.8 12.46 10.5 14.36 8.5 0.32
Serum FGF23 (pg/mL) 21586 3543 18746 3181 265464078 0.13
Serum CRP (mg/L) 9.1616.1 11.16 18.8 5.167.8 0.001
CV events in a 5-year FU, n (%) 79 (32.2) 73 (45.3) 6 (7.1) 0.0001
CV deaths in a 5-year FU, n (%) 34 (13.9) 34 (21.1) 0 0.0001
All-cause deaths in FU, n (%) 62 (25.3) 49 (30.4) 13 (15.5) 0.011
Diabetes mellitus, n (%) 76 (31) 54 (33.5) 22 (26.2) 0.24
Arterial hypertension, n (%) 235 (95.9) 159 (98.8) 76 (90.5) 0.002
Values are presented as mean6 standard deviation unless stated otherwise.
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(which represents the most differentiated SNPs between CVD
and no CVD; Supplementary data, Figure S2).
Gene ontology analysis
IPA was performed to identify possible functional roles of the
3218 selected variants. Twelve disease pathways were identified
with –log(P-value) > 7.5, among which CVD scored in the top 10
(Supplementary data, Figure S3). We focused on the disease
categories from the CVD pathway and we identified four enriched
categories with a –log(P-value) > 7.5 (Figure 1A): coronary artery
disease, coronary disease, arterial occlusion and atherosclerosis.
Gene ontology analyses using PANTHER identified the heart
development pathway as the one with the highest value of
gene enrichment (3.05-fold, P ¼ 2.65  102) (Figure 1B and
Supplementary data, Figure S4).
Selecting the only significant results from both the IPA and
PANTHER analyses resulted in the identification of two genes:
Glucagon-like peptide 1 receptor (GLP1R) and sarcoglycan delta
(SGCD) (Supplementary data, Table S4).
Tree regression analysis and CV history
The tree regression analysis was used to investigate any correla-
tion between SGCD and GLP1R genetic variants annotated in the
SNP array and any CV events or CV risk factors at the baseline.
Among the subjects homozygous for the GLP1R rs10305445 allele
A, we found a higher number of subjects with previous CV events
(81%) compared with heterozygous subjects (60% CVD) (Figure 2).
In contrast, SCGD rs145292439 allele A associated with a lower
number of subjects with previous CV events and a higher level of
high-density lipoprotein (HDL; Figure 3A), with 68% CVD among
the homozygous subjects for allele G versus 45% CVD among the
heterozygous subjects. HDL levels were lower among subjects
carrying only allele G (41.83613.84mg/dL) with respect to the
ones carrying allele A in both the homozygous and heterozygous
state (45.96614.98mg/dL). Furthermore, regression tree analysis
using age as a covariate found that individuals >59years of age
and homozygous carriers of the common allele G in SCGD have a
higher risk with respect to individuals that carry the variant al-
lele A (78% in homozygous G versus 50% in heterozygous)
(Figure 3B), confirming the age effect on CVD.
Cox regression analysis of CV events during the FU
The occurrence of CV events was analyzed with Cox regression
in patients (n¼ 245) with different genotypes at rs10305445 and
rs145292439 during the 5-year FU. The OR of CV events resulted
in an increase in homozygous patients for the GLP1R rs10305445
an allele A (n¼ 9) compared with homozygous patients for allele
G [n¼ 185; OR¼ 3.3 (95% CI 1.4–7.7), P¼ 0.006; Figure 4A]. This
finding was confirmed when we considered variables associ-
ated to CV events in the univariate analysis: gender and tertiles
of age, serum PTH and body weight [AA patients: OR 2.7 (95% CI
1.1–6.5), P¼ 0.025; GA patients: OR 1.4 (95% CI 0.8–2.5), P¼ 0.21;
GG as the reference group]. The association was still significant
after having included in the analysis variables potentially corre-
lated to CV events: gender, diabetes, arterial hypertension, ter-
tiles of age, body weight, serum phosphate, PTH and dialysis
vintage (AA patients: OR¼ 3, 95% CI 1.2–7.4, P¼ 0.019; GA
patients, OR¼ 1.4, 95% CI 0.8–2.4, P¼ 0.25; GG as the reference
group).
The Cox regression including only the patients with a clini-
cal history of CV events at the baseline (n¼ 161) confirmed that
CV events during the FU were more frequent in AA patients for
GLP1R rs10305445 [AA patients: OR 2.4 (95% CI 1–5.6), P¼ 0.043;
GA patients: OR 1.1 (95% CI 0.6–1.8), P¼ 0.86; GG as the reference
group; Figure 4B]. There was no association in patients without
previous events.
When we repeated the Cox regression in genetically unre-
lated patients (n¼ 208), again homozygous patients for GLP1R
rs10305445 allele A (n¼ 6) had a higher OR for CV events com-
pared with the homozygous patients for allele G (n¼ 164) in the
unadjusted analysis [OR 3.6 (95% CI 1.3–10), P¼ 0.015] and in the
analysis adjusted for the above-mentioned variables potentially
implicated in CV events [OR 4.1 (95% CI 1.4–12.2), P¼ 0.012].
The distribution of CV events during the FU was not related
to genotypes at SCGD rs145292439 [AA OR 1.2 (95% CI 0.4–4.1),
P¼ 0.72; GG as the reference group; data not shown].
In the Supplementary data, Tables S5 and S6 show the geno-
types distribution in our population at the two SNPs that dem-
onstrated a greater number of subjects carrying GLP1R
rs10305445 allele A (n carriers¼ 44) compared with SCGD
rs145292439 allele A (n carriers¼ 38), with allele frequencies of
0.11 and 0.09, respectively, in our sample.
Table 2. Characteristics of patients who suffered from CV events during the 5-year FU
Variables Patients CVD at FU Patients no CVD at FU P-value
n (M/F) 79 (56/23) 166 (112/54) 0.59
Age (years) 706 12 62615 0.031
Body weight (kg) 636 14 67613 0.038
Dialysis vintage (months) 706 68 58662 0.002
Serum creatinine (mg/dL) 8.316 2.31 8.3662.39 0.88
Serum calcium (mmol/L) 2.206 0.16 2.2260.19 0.39
Serum phosphate (mmol/L) 1.476 0.48 1.4860.57 0.84
Serum protein (g/dL) 6.596 0.59 6.5260.71 0.81
Serum PTH (pg/mL) 1976 155 2536211 0.039
Serum 1,25(OH)2D (pg/mL) 9.26 7.1 10.8611.2 0.31
Serum 25(OH)D (ng/mL) 13.46 13.8 136 7.4 0.85
Serum FGF23 (pg/mL) 20926 3482 219363588 0.85
Serum CRP (mg/L) 11.76 18.7 7.8614.6 0.11
Diabetes mellitus, n (%) 23 (29.1) 59 (31.9) 0.66
Arterial hypertension, n (%) 78 (98.7) 157 (94.6) 0.038
Past CV events, n (%) 73 (92.4) 88 (50) 0.0001
Values are presented as mean6 standard deviation unless stated otherwise.
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To complete the genetic analysis, we interrogated our geno-
typing array for the nine SNPs previously associated with the
risk of coronary heart diseases in CKD [20]. Only to SNPs
(WDR12 and LPA markers) were present in our genotyping array
and none were significantly associated with CV events in our
sample set (Supplementary data, Table S7).
Prediction analysis of the SNP functional activity
RegulomeDB, HaploReg v4.1 and Match 1.0 Public were
interrogated for any potential function effect of the two SNPs
associated with CV events. RegulomeDB analysis of GLP1R
rs10305445 allele A resulted in a weak binding site for the tran-
scription factor Runx-1, which was not confirmed in HaploReg,
where both alleles resulted as a potential binding site for
Runx-1. SCGS rs145292439 allele A creates a low-score binding
site for the Oct-1 and POU3F2 transcription sites, according to
RegulomeDB. The data were not confirmed by HaploReg analy-
sis, which produced changes in 11 different motifs not including
Oct-1 and POUF3F2 (see Supplementary data, Figure S5).
Match 1.0 did not identify any potential transcription bind-
ing sites around the rs10305445 and rs145292439 regions.
DISCUSSION
Our aim was to interrogate the whole-genome variants to iden-
tify any genetic marker indicative of CVD in hemodialysis
patients. We genotyped 245 hemodialysis patients using the
FIGURE 1: Gene Ontology Analysis. (A) IPA shows the enriched categories among CVD in CVD versus no CVD. The red line represents the P-value cut-off of 7.5 –log(P-
value): 12 disease pathways were identified with a log(P-value) > 7.5, among which CVD scored in the top 10. In the ‘CVD pathway’, four enriched categories with a –
log(P-value) >7.5 were identified: coronary artery disease, coronary disease, arterial occlusion and atherosclerosis. (B) PANTHER analysis resulted in the heart develop-
ment category as most significant comparing CVD versus no CVD (3.05-fold enrichment, P¼2.65  102).
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Infinium MEGAEX and correlated those variants to the history of
CV events. Previous GWASs investigated genes associated with
CKD and dialysis [32–34] and, to our knowledge, no whole-
genome variant array was performed to analyze CVD in hemo-
dialysis. Considering the small sample size, we shifted from the
GWAS analysis to a population-based approach analyzing the
Fst distance between the subjects with previous CV events
(CVD) and without events (no CVD). With this approach, we
identified 3218 SNPs differentiating the CVD group from the no
CVD group, and among these we found two gene variants re-
lated to CVD and heart development using the Gene Ontology
Analysis.
We identified an association of GLP1R rs10305445 with previ-
ous CV events and SCGD rs145292439 with no previous CV
events and a higher level of HDL, suggesting a high-risk associa-
tion of GLP1R rs10305445 with CV events, while SCGD
rs145292439 can be associated with a low risk for CVD. When
age was added as a covariate, the results for SCGD rs145292439
FIGURE 2: The tree regression analysis investigated any correlation between
SNP GLP1R rs10305445 variant allele A and CV events and risk factors. SNP GLP1R
rs10305445 statistically associated with CVD in HD patients, with 81% CVD in
subjects among those carrying the A allele compared with 60% CVD in subjects
carrying the G allele.
FIGURE 3: The tree regression analysis investigated any correlation between the
SNP SCGD rs145292439 allele A and CV events and CVD risk factors. SNP SCGD
rs145292439 significantly associated with a lower percentage of CVD (45% CVD
among the heterozygous versus 68% CVD among those homozygous for the al-
lele G) and a higher HDL level in heterozygous HD patients (A). When we in-
cluded age as covariate, the regression analyses confirmed that age (>9years)
and SCGD allele G increases CVD risk (B), with a higher percentage of CVD sub-
jects among those >59years of age and carrying allele G.
FIGURE 4: Cox regression analysis of CV events during the 5-year FU in (A) the en-
tire population of 245 patients [OR 3.3 (95% CI 1.4–7.7), P¼0.006] and in (B) 161 he-
modialysis patients with a previous history of CV events divided according to their
genotype at GLP1R rs10305445 (G>A) [AA patients: OR 2.4 (95% CI 1–5.6), P¼0.043;
GA patients: OR 1.1 (95% CI 0.6–1.8), P¼0.86; GG as the reference group].
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were significant only in subjects >59years of age, confirming
the role of the age in the risk of CVD.
Survival analysis over the 5-year FU confirmed the increase
of new CV events for patients carrying the allele A of GLP1R
rs1035445 but it did not show any protective effect of SCGD. This
result showed that the GLP1R variant has a strong predisposi-
tion towards increasing the risk of CV events in hemodialysis
patients both at baseline and at FU.
Previously GLP1R and SGCD were independently associated
with CVD and CV risk factors. GLP1R, expressed in the pancreas,
is the GLP1 receptor that is involved in blood sugar homeostasis.
GLP1R genetic variants are associated with diabetes and obesity
[35]. The GLP1R rs6923761 variant allele was demonstrated to
improve weight loss after bariatric surgery and to reduce CV co-
morbidity [36]. Another study found similar results with GLP1R
rs10305492, which is associated with a lower risk of diabetes
and increased protection for coronary heart disease [37].
Recently GLP1R has been targeted for therapeutic treatment in
CKD patients affected by type 2 diabetes. Although the clinical
experience is still limited, GLP1R agonists are promising alter-
natives to the use of glucose-lowering agents in CKD diabetic
patients [38]. Our study suggests that the genetic background
should be considered as a factor affecting the response to the
treatment and that a pharmacogenomic approach could pro-
duce stronger results.
SGCD was associated with the heart and muscle develop-
ment in Drosophila models and confirmed in a GWAS human
study that identified rs6877118 as associated with plasma HDL
[39, 40]. Interestingly the SGCD variant associated with lower
risk of CV events is practically absent in Africa (allele frequency
¼ 0.002) and East Asia subjects, instead is present in Europeans
(allele frequency ¼ 0.07) (1000 genome database) [41].
A previous study identified a genetic risk of coronary heart
diseases in CKD using a multilocus genetic risk score from nine
genetic variants [20]. None of these variants include the two
SNPs that we identified in our study, probably due to selection
of the nine variants from a healthy-population GWAS. We then
analyzed the frequency of the nine SNPs in our sample set and
only two SNPs (WDR12 and LPAmarkers) were present in our ar-
ray, and none of them were significantly associated with CV
events in our population.
Both SNPs are noncoding intronic variants and their effect
on gene function is unknown. We preliminarily explored predic-
tive tools (RegulomeDB [29], HaploReg 4.1 [30] and Match 1.0
Public [31]) to identify functional effects on gene function (gene
transcription), but we did not find any significant and consis-
tent results. An in vitro model to test the two variants will be
useful to characterize them.
A limitation of our study is indeed the sample size and for
this reason we opted for a population-based approach to dis-
cover variants that could affect the number of CV events in our
sample. Further studies should be focused on increasing the
sample size and to use of whole-genome sequencing to discover
rare deleterious variants affecting CV risk in dialysis patients.
Furthermore, we aim to test these two variants of GLP1R and
SCGD using in vitromodel to understand their role.
The results of our study reinforce the concept of precision
medicine that aims to tailor treatments and prevention to the
patient’s genetic background in order to identify high-risk
patients and to improve the success rate of therapy.
In conclusion, our study identified two SNPs (rs10305445 and
rs145292439) in the genes GLP1R and SCGD, respectively, that
can contribute to the higher risk of CVD in CKD patients on
hemodialysis, allowing better stratification of the CV risk in
patients with CKD.
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